Stimulating Growth: St. Jude buys ANS
Executive Summary
Is there a hotter sector in medical devices today than neuromodulation/neurostimulation? Just a year after Boston Scientific leapt into the market by paying a huge amount of money--$740 million not counting earn-outs--for Advanced Bionics, St. Jude Medical tops that with its recently announced $1.3 billion deal for neuromodulation leader Advanced Neuromodulation Systems. (ANS). The acquisition offers St. Jude an additional growth platform outside its existing product offerings in cardiac rhythm management (particularly ICDs), atrial fibrillation, and cardiology.
You may also be interested in...
Building Medtronic Neuro by Trial: An Interview with Richard Kuntz, MD
Medtronic is the acknowledged leader in one of the hottest device sectors-neurostimulation-but even this giant struggles with problems of limited market penetration. So Medtronic is bringing a new approach to this area: an aggressive clinical trials strategy to differentiate its products and drive physician adoption. Who better to run the business than a clinical trials expert? Richard Kuntz talks about future neuro opportunities and the current challenges facing device clinical trials.
Neurostimulation Market Expanding
According to Medtech Insight’s recently published report, US Markets for Neurostimulation Products, the frontier for neural stimulation is expanding rapidly, representing a $628 million market in 2006 that is forecast to grow by over 20% each year to produce sales approaching $2 billion in 2012. Topics discussed include implantable pulse generators, device reimbursement, and current and emerging applications for neurostimulation.
What next for Guidant and J&J?
With the announced launch of a criminal investigation into Guidant's marketing practices by the New York State Attorney General's office and an SEC inquiry into product disclosures and Guidant's stock trading coming on the heels of the clearance of the deal by the Federal Trade Commission (FTC), news reports seemed divided on whether the $25.4 billion mega-merger of Guidant Corp. and Johnson & Johnson was actually going to take place. Some industry analysts said the deal was essentially dead; others cited analysts just as certain that the deal would get done in some form or another.